FLX Bio Secures $50,000,000 Series B Financing

  • Feed Type
  • Date
    4/30/2016
  • Company Name
    FLX Bio
  • Mailing Address
    561 Eccles Avenue South San Francisco, CA 94080 USA
  • Company Description
    Founded in 2015, FLX Bio Inc. is a privately-held biopharmaceutical company focused on the discovery, development and commercialization of novel immuno-oncology agents.
  • Website
    http://www.flxbio.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $50,000,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    The funds will be used to support further discovery and development of its pipeline of novel immuno-oncology compounds and to advance development of the company’s Phase 1 clinical compound, FLX925, a selective inhibitor of FLT3 and CDK4/6, in a proof-of-concept study in patients with acute myeloid leukemia.
  • M&A Terms
  • Venture Investor
    The Column Group
  • Venture Investor
    Topspin Partners
  • Venture Investor
    Kleiner Perkins Caufield & Byers
  • Venture Investor
    Celgene

Trending on Xconomy